The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL / ACCESS Newswire / February 20, 2025 / Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Giftify (GIFT) announced that CardCash.com is offering consumers smart saving solutions for high-cost GLP-1 weight loss prescription ...

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

President Trump is going scorched earth on America’s major European trading partners. Vowing to impose reciprocal tariffs on ...

These super high-flying US stocks have soared 222%, 122%, and 150%, respectively, in 2025. Let's take a look why.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...